Emilio Vanoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1949502/publications.pdf

Version: 2024-02-01

201674 128289 3,610 87 27 60 h-index citations g-index papers 92 92 92 2959 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. Heart Failure Reviews, 2020, 25, 295-303.	3.9	24
2	Current challenges in sudden cardiac death prevention. Heart Failure Reviews, 2020, 25, 99-106.	3.9	7
3	CardioMEMS, the real progress in heart failure home monitoring. Heart Failure Reviews, 2020, 25, 93-98.	3.9	9
4	The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. European Heart Journal Supplements, 2020, 22, L77-L81.	0.1	15
5	Use of dual-flow bioreactor to develop a simplified model of nervous-cardiovascular systems crosstalk: A preliminary assessment. PLoS ONE, 2020, 15, e0242627.	2.5	8
6	Title is missing!. , 2020, 15, e0242627.		0
7	Title is missing!. , 2020, 15, e0242627.		O
8	Title is missing!. , 2020, 15, e0242627.		0
9	Title is missing!. , 2020, 15, e0242627.		O
10	Title is missing!. , 2020, 15, e0242627.		0
11	Title is missing!. , 2020, 15, e0242627.		0
12	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. Journal of the Neurological Sciences, 2019, 405, 116423.	0.6	6
13	Proarrhythmic proclivity of left-stellate ganglion stimulation in a canine model of drug-induced long-QT syndrome type 1. International Journal of Cardiology, 2019, 286, 66-72.	1.7	17
14	Unresolved issues in left ventricular postischemic remodeling and progression to heart failure. Journal of Cardiovascular Medicine, 2019, 20, 640-649.	1.5	21
15	Peripheral Blood Mononuclear Cell Therapy for the Treatment of Lower Limb Ischemia in Diabetic Patients: Is It Really True?. Annals of Vascular Surgery, 2019, 56, 359-360.	0.9	O
16	Letter to "Correlation between pulmonary artery pressure and thoracic impedance: Insights from daily monitoring through an implanted device in chronic heart failure― International Journal of Cardiology, 2018, 259, 185.	1.7	0
17	AnatoMy and physlopathoLogy of the heArt in a ceNtenarian cOhort (MILANO study). American Heart Journal, 2018, 205, 12-20.	2.7	2

#	Article	IF	CITATIONS
19	Baroflex Activation Therapy for Refractory Congestive Heart Failure: Anesthetic Implications. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, 1103-1108.	1.3	1
20	Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy. Journal of Hypertension, 2017, 35, 2532-2536.	0.5	28
21	Baroreflex activation therapy. Journal of Cardiovascular Medicine, 2017, 18, 641-649.	1.5	24
22	Remote heart function monitoring. Journal of Cardiovascular Medicine, 2016, 17, 518-523.	1.5	7
23	Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure. Clinical Research in Cardiology, 2016, 105, 838-846.	3.3	22
24	Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure. Current Heart Failure Reports, 2016, 13, 273-280.	3.3	5
25	Cardiac Rhythm Monitoring After Acute Decompensation for Heart Failure: Results from the CARRYING ON for HF Pilot Study. JMIR Research Protocols, 2016, 5, e62.	1.0	5
26	Autonomic Pathophysiology After Myocardial Infarction Falling into Heart Failure. , 2016, , 73-85.		0
27	Baroreceptor activation therapy: The importance of targeting the right patient: who needs to be treated?. European Journal of Heart Failure, 2015, 17, 1000-1002.	7.1	5
28	Challenges in personalised management of chronic diseasesâ€"heart failure as prominent example to advance the care process. EPMA Journal, 2015, 7, 2.	6.1	35
29	Long-term chronic baroreflex activation. Journal of Hypertension, 2015, 33, 1704-1708.	0.5	42
30	Baroreflex activation therapy for the treatment of heart failure. Interventional Cardiology, 2015, 7, 559-569.	0.0	1
31	Risk for Sudden Cardiac Death in Heart Failure: Underlying Mechanisms and Therapeutic Modalities. , 2015, , 129-149.		0
32	Vagomimetic Effects of Fingolimod: Physiology and Clinical Implications. CNS Neuroscience and Therapeutics, 2014, 20, 496-502.	3.9	14
33	Novel approaches to the post-myocardial infarction/heart failure neural remodeling. Heart Failure Reviews, 2014, 19, 611-619.	3.9	15
34	The Baroreceptor as a Therapeutic Target for Heart Failure. Journal of Cardiovascular Translational Research, 2014, 7, 301-309.	2.4	9
35	Striking improvement in a case of reduced ejection fraction heart failure with baroreflex activation therapy. Journal of Cardiology Cases, 2014, 10, 4-6.	0.5	1
36	Rat Experimental Model of Myocardial Ischemia/Reperfusion Injury: An Ethical Approach to Set up the Analgesic Management of Acute Post-Surgical Pain. PLoS ONE, 2014, 9, e95913.	2.5	14

#	Article	IF	CITATIONS
37	Adaptive servo ventilation reduces central sleep apnea in chronic heart failure patients. Journal of Cardiovascular Medicine, 2013, 14, 296-300.	1.5	15
38	Dietary Omega-3 Fatty Acids and Susceptibility to Ventricular Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 553-560.	4.8	28
39	Vagal Reflexes Following an Exercise Stress Test. Journal of the American College of Cardiology, 2012, 60, 2515-2524.	2.8	51
40	La vulnerabilità cardiaca della donna agli stressor acuti: La sindrome Tako-tsubo. , 2012, , 239-249.		0
41	NGF and heart: Is there a role in heart disease?. Pharmacological Research, 2011, 63, 266-277.	7.1	50
42	Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial. Cardiovascular Therapeutics, 2011, 29, 89-98.	2.5	15
43	Vagal Stimulation, Through its Nicotinic Action, Limits Infarct Size and the Inflammatory Response to Myocardial Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 2011, 58, 500-507.	1.9	163
44	Assessing the pattern of ST-segment depression during subendocardial ischemia using a computer simulation of the ventricular electrogram. Journal of Electrocardiology, 2009, 42, 12-18.	0.9	3
45	Stress-induced QTc-interval shortening as an ancillary marker of ischemia in patients with complete left bundle branch block. Journal of Cardiovascular Medicine, 2009, 10, 376-382.	1.5	0
46	Multislice computed tomography for the evaluation of coronary bypass grafts and native coronary arteries: comparison with traditional angiography. Journal of Cardiovascular Medicine, 2009, 10, 454-460.	1.5	11
47	Neural Control of Heart Rate Is an Arrhythmia Risk Modifier in Long QT Syndrome. Journal of the American College of Cardiology, 2008, 51, 920-929.	2.8	99
48	Prediction of unexpected sudden death among healthy dogs by a novel marker of autonomic neural activity. Heart Rhythm, 2008, 5, 300-305.	0.7	30
49	Sympathomimetic inefficiency in restoring contractility in the acute or chronic βâ€blockerâ€treated ischaemic heart: Comparison with a new agent. European Journal of Heart Failure, 2008, 10, 990-996.	7.1	6
50	From exercise training to sudden death prevention via adrenergic receptors. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2631-H2633.	3.2	3
51	Baroreflex Sensitivity Predicts Long-Term Cardiovascular Mortality After Myocardial Infarction Even in Patients With Preserved Left Ventricular Function. Journal of the American College of Cardiology, 2007, 50, 2285-2290.	2.8	143
52	Istaroxime: A New Luso-Inotropic Agent for Heart Failure. American Journal of Cardiology, 2007, 99, S33-S40.	1.6	39
53	Sudden Death Prevention in Heart Failure: The Case of CIBIS III. Heart International, 2006, 2, 182618680600200.	1.4	0
54	What does the future hold for the management of chronic heart failure?. Country Review Ukraine, 2006, 8, C51-C57.	0.8	2

#	Article	IF	CITATIONS
55	Sudden death prevention in heart failure: The case of CIBIS III. Heart International, 2006, 2, 73.	1.4	6
56	Phenotypic Variability and Unusual Clinical Severity of Congenital Long-QT Syndrome in a Founder Population. Circulation, 2005, 112, 2602-2610.	1.6	179
57	Ephedrine increases ventricular arrhythmias in conscious dogs after myocardial infarction. Journal of the American College of Cardiology, 2004, 44, 1675-1678.	2.8	13
58	Heterogeneous Regional Endocardial Repolarization is Associated with Increased Risk for Ischemiaâ€Dependent Ventricular Fibrillation after Myocardial Infarction. Journal of Cardiovascular Electrophysiology, 2003, 14, 873-879.	1.7	22
59	Hemodynamic Effects of a New Inotropic Compound, PST-2744, in Dogs With Chronic Ischemic Heart Failure. Journal of Cardiovascular Pharmacology, 2003, 42, 169-173.	1.9	30
60	Autonomic Modulation during Acute Myocardial Ischemia by Low-Dose Pirenzepine in Conscious Dogs with a Healed Myocardial Infarction: A Comparison with β-Adrenergic Blockade. Journal of Cardiovascular Pharmacology, 2003, 41, 671-677.	1.9	8
61	Combined Sodium and Calcium Channel Blockade in Prevention of Lethal Arrhythmias. Journal of Cardiovascular Pharmacology, 2003, 41, 665-670.	1.9	3
62	Early autonomic and repolarization abnormalities contribute to lethal arrhythmias in chronic ischemic heart failure. Journal of the American College of Cardiology, 2001, 37, 1741-1748.	2.8	40
63	Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). American Heart Journal, 2001, 142, 989-997.	2.7	14
64	Five-minute recording of heart rate variability in severe chronic heart failure: Correlates with right ventricular function and prognostic implications. American Heart Journal, 2000, 139, 1088-1095.	2.7	65
65	Therapeutical Options to Influence the Autonomic Nervous System. Developments in Cardiovascular Medicine, 2000, , 69-86.	0.1	0
66	Antifibrillatory efficacy of ersentilide, a novel \hat{l}^2 -adrenergic and lkr blocker, in conscious dogs with a healed myocardial infarction. Cardiovascular Research, 1998, 40, 56-63.	3.8	12
67	Technology and Physiology of Baroreflex Sensitivity. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 352-353.	1.0	2
68	Muscarinic Effects on Action Potential Duration and its Rate Dependence in Canine Purkinje Fibers. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 2023-2026.	1.2	7
69	K+ Channel Blockade in the Prevention of Ventricular Fibrillation in Dogs with Acute Ischemia and Enhanced Sympathetic Activity. Journal of Cardiovascular Pharmacology, 1995, 26, 847-854.	1.9	21
70	Sympathetic activation, ventricular repolarization and Ikrblockade: Implications for the antifibrillatory efficacy of potassium channel blocking agents. Journal of the American College of Cardiology, 1995, 25, 1609-1614.	2.8	43
71	Do Increases in Markers of Vagal Activity Imply Protection From Sudden Death?. Circulation, 1995, 91, 2516-2519.	1.6	70
72	Heart Rate Variability During Specific Sleep Stages. Circulation, 1995, 91, 1918-1922.	1.6	277

#	Article	IF	CITATIONS
73	Alpha1-Adrenergic Blockade and Sudden Cardiac Death. Journal of Cardiovascular Electrophysiology, 1994, 5, 76-89.	1.7	10
74	Baroreflex Sensitivity: Methods, Mechanisms, and Prognostic Value. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 434-445.	1.2	30
75	Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. Journal of the American College of Cardiology, 1993, 22, 1327-1334.	2.8	91
76	Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine. American Heart Journal, 1992, 124, 883-890.	2.7	53
77	Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction Circulation Research, 1991, 68, 1471-1481.	4.5	642
78	Heart rate variability before and after myocardial infarction in conscious dogs at high and low risk of sudden death. Journal of the American College of Cardiology, 1990, 16, 978-985.	2.8	134
79	Tocainide and mortality after myocardial infarction: A prospective study in conscious dogs. Journal of the American College of Cardiology, 1990, 16, 1475-1480.	2.8	3
80	Carbon monoxide and lethal arrhythmias in conscious dogs with a healed myocardial infarction. American Heart Journal, 1989, 117, 348-357.	2.7	12
81	Response of cytochrome a, a3 to carbon monoxide in canine hearts with prior infarcts. Life Sciences, 1988, 42, 927-931.	4.3	10
82	Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction Circulation, 1988, 78, 969-979.	1.6	555
83	Efficacy of diltiazem in two experimental feline models of sudden cardiac death. Journal of the American College of Cardiology, 1986, 8, 661-668.	2.8	29
84	Mexiletine in the Prevention of Sudden Cardiac Death: Experimental Evaluation and Clinical Implications. Clinical Progress in Electrophysiology and Pacing, 1986, 4, 595-601.	0.1	0
85	Lack of correlation between occlusion and reperfusion arrhythmias in the cat. American Heart Journal, 1985, 109, 932-936.	2.7	11
86	The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity. American Heart Journal, 1985, 109, 937-948.	2.7	113
87	Cardiac Arrhythmias Elicited by Interaction Between Acute Myocardial Ischemia and Sympathetic Hyperactivity. Journal of Cardiovascular Pharmacology, 1981, 3, 1251-1259.	1.9	109